Tim Van den Wyngaert

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2548184/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Update on imaging in chronic kidney disease-mineral and bone disorder: promising role of functional imaging. Skeletal Radiology, 2022, 51, 905-922.	1.2	1
2	Effect of sodium administration on fluid balance and sodium balance in health and the perioperative setting. Extended summary with additional insights from the MIHMoSA and TOPMAST studies. Journal of Critical Care, 2022, 67, 157-165.	1.0	8
3	PET/MRI as a research tool in musculoskeletal conditions. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2022, , .	0.4	2
4	Gamma camera imaging (bone scan) in orthopedics: Foot, ankle, knees, and hip. , 2022, , .		0
5	Improved Characteristics of RANKL Immuno-PET Imaging Using Radiolabeled Antibody Fab Fragments. Pharmaceutics, 2022, 14, 939.	2.0	4
6	Radionuclide Imaging of Cytotoxic Immune Cell Responses to Anti-Cancer Immunotherapy. Biomedicines, 2022, 10, 1074.	1.4	3
7	Dual time point imaging in locally advanced head and neck cancer to assess residual nodal disease after chemoradiotherapy. EJNMMI Research, 2022, 12, .	1.1	1
8	Immuno-PET Molecular Imaging of RANKL in Cancer. Cancers, 2021, 13, 2166.	1.7	3
9	The clinical effectiveness of reconstructing ¹⁸ F-sodium fluoride PET/CT bone using Bayesian penalized likelihood algorithm for evaluation of metastatic bone disease in obese patients. British Journal of Radiology, 2021, 94, 20210043.	1.0	4
10	Molecular Imaging of Apoptosis: The Case of Caspase-3 Radiotracers. International Journal of Molecular Sciences, 2021, 22, 3948.	1.8	48
11	Bone SPECT/CT in the Evaluation of Painful Total Ankle Replacement. Clinical Nuclear Medicine, 2021, 46, 361-368.	0.7	5
12	Early Changes in [18F]FDG Uptake as a Readout for PI3K/Akt/mTOR Targeted Drugs in HER-2-Positive Cancer Xenografts. Molecular Imaging, 2021, 2021, 1-14.	0.7	3
13	Fluid-induced harm in the hospital: look beyond volume and start considering sodium. From physiology towards recommendations for daily practice in hospitalized adults. Annals of Intensive Care, 2021, 11, 79.	2.2	22
14	EANM recommendations based on systematic analysis of small animal radionuclide imaging in inflammatory musculoskeletal diseases. EJNMMI Research, 2021, 11, 85.	1.1	6
15	18F-Sodium Fluoride (NaF) PET/CT in obese patients on LYSO PET/CT system: Patient dosimetry, optimization of injected activity and acquisition time. Journal of Nuclear Medicine Technology, 2021, 49, jnmt.120.258137.	0.4	1
16	If prophylactic HPV vaccination is considered in a woman with CIN2+, what is the value and should it be given before or after the surgical treatment?. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 269, 98-101.	0.5	7
17	Absolute Quantification in Diagnostic SPECT/CT: The Phantom Premise. Diagnostics, 2021, 11, 2333.	1.3	7
18	Development of Antibody Immuno-PET/SPECT Radiopharmaceuticals for Imaging of Oncological Disorders—An Update. Cancers, 2020, 12, 1868.	1.7	33

#	Article	IF	CITATIONS
19	Quality Assessment in FDG-PET/CT Imaging of Head-and-Neck Cancer: One Home Run Is Better Than Two Doubles. Frontiers in Oncology, 2020, 10, 1458.	1.3	9
20	SPECT/CT: Standing on the Shoulders of Giants, It Is Time to Reach for the Sky!. Journal of Nuclear Medicine, 2020, 61, 1284-1291.	2.8	50
21	Quantification of 18F-fluorodeoxyglucose uptake to detect residual nodal disease in locally advanced head and neck squamous cell carcinoma after chemoradiotherapy: results from the ECLYPS study. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1075-1082.	3.3	10
22	Preventing, identifying, and managing medication-related osteonecrosis of the jaw: a practical guide for nurses and other allied healthcare professionals. Supportive Care in Cancer, 2020, 28, 4019-4029.	1.0	24
23	¹⁸ F-Flortanidazole Hypoxia PET Holds Promise as a Prognostic and Predictive Imaging Biomarker in a Lung Cancer Xenograft Model Treated with Metformin and Radiotherapy. Journal of Nuclear Medicine, 2019, 60, 34-40.	2.8	20
24	Effects of metformin on tumor hypoxia and radiotherapy efficacy: a [18F]HX4 PET imaging study in colorectal cancer xenografts. EJNMMI Research, 2019, 9, 74.	1.1	11
25	154 compared to 54Âmmol per liter of sodium in intravenous maintenance fluid therapy for adult patients undergoing major thoracic surgery (TOPMAST): a single-center randomized controlled double-blind trial. Intensive Care Medicine, 2019, 45, 1422-1432.	3.9	40
26	RANK-RANKL Signaling in Cancer of the Uterine Cervix: A Review. International Journal of Molecular Sciences, 2019, 20, 2183.	1.8	22
27	Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability. PLoS ONE, 2019, 14, e0215135.	1.1	6
28	Bloodpool SPECT as part of bone SPECT/CT in painful total knee arthroplasty (TKA): validation and potential biomarker of prosthesis biomechanics. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1009-1018.	3.3	20
29	Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2019, 127, 117-135.	0.2	198
30	Molecular imaging of bone metastases using bone targeted tracers. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 112-128.	0.4	9
31	Bone metastases in the era of targeted treatments: insights from molecular biology. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 98-111.	0.4	8
32	Quantitative radionuclide imaging of bone metastases. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 129-135.	0.4	4
33	The changing role of radium-223 in metastatic castrate-resistant prostate cancer: has the EMA missed the mark with revising the label?. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 170-182.	0.4	7
34	Ovarian cancer unmasked by technetium-99m bone scintigraphy and single-photon emission computed tomography. World Journal of Nuclear Medicine, 2019, 18, 58.	0.3	2
35	Radionuclide imaging and therapy of bone metastases in the era of targeted therapy. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 95-97.	0.4	0
36	Bone mineral density in adolescent elite ballet dancers. Journal of Sports Medicine and Physical Fitness, 2019, 59, 1564-1570.	0.4	3

#	Article	IF	CITATIONS
37	FDG-PET/CT for treatment response assessment in head and neck squamous cell carcinoma: a systematic review and meta-analysis of diagnostic performance. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1063-1071.	3.3	58
38	The role of hybrid bone SPECT/CT imaging in the work-up of the limping patient: a symptom-based and joint-oriented review. European Journal of Hybrid Imaging, 2018, 2, 8.	0.6	14
39	SPECT/CT in Postoperative Foot and Ankle Pain. Seminars in Nuclear Medicine, 2018, 48, 454-468.	2.5	30
40	Cost-Effectiveness of Bone SPECT/CT in Painful Total Knee Arthroplasty. Journal of Nuclear Medicine, 2018, 59, 1742-1750.	2.8	20
41	Maintenance fluid therapy and fluid creep impose more significant fluid, sodium, and chloride burdens than resuscitation fluids in critically ill patients: a retrospective study in a tertiary mixed ICU population. Intensive Care Medicine, 2018, 44, 409-417.	3.9	128
42	Occult capitate fracture through a bone island – SPECT/CT arthrography imaging. European Journal of Hybrid Imaging, 2018, 2, .	0.6	2
43	How to Modulate Tumor Hypoxia for Preclinical In Vivo Imaging Research. Contrast Media and Molecular Imaging, 2018, 2018, 1-17.	0.4	6
44	SPECT/CT in the Postoperative Painful Knee. Seminars in Nuclear Medicine, 2018, 48, 439-453.	2.5	34
45	SPECT/CT in Postoperative Hand and Wrist Pain. Seminars in Nuclear Medicine, 2018, 48, 396-409.	2.5	16
46	Bone SPECT/CT in Postoperative Spine. Seminars in Nuclear Medicine, 2018, 48, 410-424.	2.5	26
47	SPECT/CT in Postoperative Painful Hip Arthroplasty. Seminars in Nuclear Medicine, 2018, 48, 425-438.	2.5	44
48	The predictive value of sentinel node biopsy in early breast cancer after neo-adjuvant chemotherapy: A prospective study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2018, 229, 108-111.	0.5	3
49	Technical feasibility, radiation dosimetry and clinical use of 18F-sodium fluoride (NaF) in evaluation of metastatic bone disease in pediatric population. Annals of Nuclear Medicine, 2018, 32, 594-601.	1.2	4
50	Letter from the Guest Editors. Seminars in Nuclear Medicine, 2018, 48, 395.	2.5	0
51	Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treatment Reviews, 2018, 69, 177-187.	3.4	194
52	Usefulness of splenic scintigraphy in differentiating splenosis and malignancy on gallium 68 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-NaI3-octreotide. World Journal of Nuclear Medicine, 2018, 17, 56-58.	0.3	4
53	Evaluation of [18F]Fluorothymidine as a Biomarker for Early Therapy Response in a Mouse Model of Colorectal Cancer. Molecular Imaging and Biology, 2017, 19, 109-119.	1.3	2
54	A patient with a severe glottic stenosis and saddle nose. Acta Clinica Belgica, 2017, 72, 130-132.	0.5	3

#	Article	IF	CITATIONS
55	Characterization of an Orthotopic Colorectal Cancer Mouse Model and Its Feasibility for Accurate Quantification in Positron Emission Tomography. Molecular Imaging and Biology, 2017, 19, 762-771.	1.3	6
56	Effect of isotonic versus hypotonic maintenance fluid therapy on urine output, fluid balance, and electrolyte homeostasis: a crossover study in fasting adult volunteers. British Journal of Anaesthesia, 2017, 118, 892-900.	1.5	45
57	Evaluation of [18F]CP18 as a Substrate-Based Apoptosis Imaging Agent for the Assessment of Early Treatment Response in Oncology. Molecular Imaging and Biology, 2017, 19, 560-569.	1.3	16
58	Neoadjuvant systemic therapy in breast cancer: Challenges and uncertainties. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2017, 210, 144-156.	0.5	29
59	Diagnostic Challenge of Staging Metastatic Bone Disease in the Morbidly Obese Patients. Clinical Nuclear Medicine, 2017, 42, 829-836.	0.7	8
60	Bone SPECT/CT in the postoperative spine: a focus on spinal fusion. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2094-2104.	3.3	32
61	18F-FDG-PET/CT for the detection of disease in patients with head and neck cancer treated with radiotherapy. PLoS ONE, 2017, 12, e0182350.	1.1	23
62	Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography After Concurrent Chemoradiotherapy in Locally Advanced Head-and-Neck Squamous Cell Cancer: The ECLYPS Study. Journal of Clinical Oncology, 2017, 35, 3458-3464.	0.8	45
63	Introducing TOPMAST, the first double-blind randomized clinical trial specifically dedicated to perioperative maintenance fluid therapy in adults. Anaesthesiology Intensive Therapy, 2017, 49, 366-372.	0.4	5
64	Abstract P2-01-02: The predictive value of sentinel node biopsy (SNB) in early breast cancer after neo-adjuvant chemotherapy (NACT): A prospective study. , 2017, , .		0
65	Abstract 1875: [18F]HX4 shows potential as a predictive biomarker for the radiosensitizing capacities of metformin in a NSCLC xenograft model. , 2017, , .		0
66	Prediction vs. Prognostication and Guarantee-Time Bias: Steering Clear of the Pitfalls of Interpreting Observational Data. Journal of Nuclear Medicine, 2016, 57, 990-990.	2.8	1
67	Preoperative ultrasound staging of the axilla make's peroperative examination of the sentinel node redundant in breast cancer: saving tissue, time and money. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2016, 206, 164-171.	0.5	8
68	Reply to: Starck et al European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2265-2266.	3.3	0
69	Impact of chloride and strong ion difference on ICU and hospital mortality in a mixed intensive care population. Annals of Intensive Care, 2016, 6, 91.	2.2	42
70	The EANM practice guidelines for bone scintigraphy. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1723-1738.	3.3	293
71	Baseline [18F]FMISO μPET as a Predictive Biomarker for Response to HIF-1α Inhibition Combined with 5-FU Chemotherapy in a Human Colorectal Cancer Xenograft Model. Molecular Imaging and Biology, 2016, 18, 606-616.	1.3	11
72	ECLYPS: Multicenter trial of FDG-PET/CT to detect residual nodal disease in locally advanced head-and-neck squamous cell carcinoma (LAHNSCC) after chemoradiotherapy (CRT) Journal of Clinical Oncology, 2016, 34, 6021-6021.	0.8	2

#	Article	IF	CITATIONS
73	18F-NaF PET/CT: EANM procedure guidelines for bone imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1767-1777.	3.3	123
74	Reproducibility of Lymphoscintigraphic Evaluation of the Upper Limb. Lymphatic Research and Biology, 2014, 12, 175-184.	0.5	17
75	Prospective observational study of treatment pattern, effectiveness and safety of zoledronic acid therapy beyond 24 months in patients with multiple myeloma or bone metastases from solid tumors. Supportive Care in Cancer, 2013, 21, 3483-3490.	1.0	19
76	RapidArc, SmartArc and TomoHD compared with classical step and shoot and sliding window intensity modulated radiotherapy in an oropharyngeal cancer treatment plan comparison. Radiation Oncology, 2013, 8, 37.	1.2	45
77	Early Effect of PI3K-AKT-MTOR Blockade On in Vitro 18F-FDG Uptake in HER2+ Breast Cancer Resistant to Trastuzumab. Annals of Oncology, 2013, 24, iii40.	0.6	0
78	593 The Role of Sentinel Node (SLN) Procedure After Neo-adjuvant Chemotherapy (NACT) for Node Positive Breast Cancer (NPBC). European Journal of Cancer, 2012, 48, S218.	1.3	0
79	Topical Honey Application to Reduce Radiation-Induced Oral Mucositis: A Therapy too Sweet to Ignore?. Journal of Evidence-based Dental Practice, 2012, 12, 203-205.	0.7	10
80	Abstract P3-13-01: Prospective study of treatment pattern, effectiveness, and safety of zoledronic acid (ZOL) therapy beyond 24 months: subgroup analysis of patients (pts) with metastatic bone disease (MBD) from breast cancer (BC) , 2012, , .		0
81	3060 POSTER Renal Safety of Zoledronic Acid (ZOL) in Patients (pts) Starting ZOL Therapy and Beyond 2 Years of Treatment – a Prospective Multi-center Evaluation. European Journal of Cancer, 2011, 47, S240.	1.3	1
82	Prognostic Value of Bone Scintigraphy in Cancer Patients With Osteonecrosis of the Jaw. Clinical Nuclear Medicine, 2011, 36, 17-20.	0.7	19
83	RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem?. Supportive Care in Cancer, 2011, 19, 2035-2040.	1.0	54
84	Scintigraphic evaluation of mandibular bone turnover in patients with solid tumors receiving zoledronic acid. Oral Oncology, 2010, 46, 214-218.	0.8	12
85	Lymphomatous Meningosis Diagnosed with [¹⁸ F]-Fluorodeoxyglucose–Positron-Emission Tomography/CT. American Journal of Neuroradiology, 2009, 30, E150-E151.	1.2	0
86	Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome. Annals of Oncology, 2009, 20, 331-336.	0.6	119
87	Bisphosphonates in Oncology: Rising Stars or Fallen Heroes. Oncologist, 2009, 14, 181-191.	1.9	33
88	Disambiguating the bisphosphonates. Annals of Oncology, 2008, 19, 1357-1359.	0.6	5
89	Osteonecrosis of the jaw related to the use of bisphosphonates. Current Opinion in Oncology, 2007, 19, 315-322.	1.1	71
90	Osteonecrosis of the Jaw (ONJ) Might Explain the Increased Oral Surgery Risk in Cancer Patients Treated with Bisphosphonates. Journal of Evidence-based Dental Practice, 2007, 7, 132-135.	0.7	8

#	Article	IF	CITATIONS
91	Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy?. Annals of Oncology, 2006, 17, 1197-1204.	0.6	102